Erste Asset Management GmbH Has $507,000 Stake in Amicus Therapeutics, Inc. $FOLD

Erste Asset Management GmbH reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 45.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,850 shares of the biopharmaceutical company’s stock after selling 53,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Amicus Therapeutics were worth $507,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Osaic Holdings Inc. increased its stake in shares of Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the period. Strs Ohio acquired a new position in Amicus Therapeutics during the first quarter worth approximately $30,000. ANTIPODES PARTNERS Ltd bought a new stake in Amicus Therapeutics in the third quarter valued at approximately $31,000. Finally, Versant Capital Management Inc lifted its position in shares of Amicus Therapeutics by 499.1% in the third quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,387 shares during the last quarter.

Analyst Upgrades and Downgrades

FOLD has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Needham & Company LLC cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Citigroup reiterated a “neutral” rating and issued a $14.50 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Zacks Research lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Finally, Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $15.39.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $14.37 on Monday. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of -179.63 and a beta of 0.43. The stock’s fifty day moving average price is $14.29 and its two-hundred day moving average price is $10.71. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. During the same period in the prior year, the business posted $0.09 EPS. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. On average, equities analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total value of $1,073,250.00. Following the completion of the sale, the chief executive officer directly owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Michael Clark sold 25,642 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $14.17, for a total value of $363,347.14. Following the completion of the sale, the insider owned 245,690 shares of the company’s stock, valued at approximately $3,481,427.30. This trade represents a 9.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 204,211 shares of company stock valued at $2,564,947 in the last three months. Insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.